A pivotal trial showed that semaglutide, a GLP-1 receptor agonist, improved symptoms in patients with heart failure, obesity, and diabetes, similar to those without diabetes. The trial, conducted in patients with heart failure with preserved ejection fraction (HFpEF), obesity, and type 2 diabetes, demonstrated significant weight loss and improvement in quality of life compared to a placebo. Semaglutide also showed benefits in reducing heart failure-related symptoms, improving physical function, and reducing the risk of serious adverse events. The study suggested that semaglutide could be a valuable therapeutic approach for managing patients with obesity-related HFpEF, especially when combined with type 2 diabetes.
Source link
Semaglutide Beneficial in HFpEF Patients With Diabetes
